CA2372960C - Hiv immunogenic compositions and methods - Google Patents

Hiv immunogenic compositions and methods Download PDF

Info

Publication number: CA2372960C
Authority: CA; Canada
Prior art keywords: hiv; immunogenic composition; nucleic acid; acid molecule; antigen
Prior art date: 1999-05-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002372960A

Other languages

English (en)

French (fr)

Other versions

CA2372960A1 (en

Inventor

Ronald B. Moss

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Immune Response Corp

Original Assignee

Immune Response Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-06

Filing date

2000-05-05

Publication date

2006-03-28

2000-05-05 Application filed by Immune Response Corp filed Critical Immune Response Corp

2000-11-16 Publication of CA2372960A1 publication Critical patent/CA2372960A1/en

2006-03-28 Application granted granted Critical

2006-03-28 Publication of CA2372960C publication Critical patent/CA2372960C/en

2020-05-05 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 165
230000002163 immunogen Effects 0.000 title claims abstract description 126
238000000034 method Methods 0.000 title abstract description 37
241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 177
238000004519 manufacturing process Methods 0.000 claims abstract description 79
108020004707 nucleic acids Proteins 0.000 claims abstract description 62
102000039446 nucleic acids Human genes 0.000 claims abstract description 62
150000007523 nucleic acids Chemical class 0.000 claims abstract description 62
239000002671 adjuvant Substances 0.000 claims abstract description 60
241000124008 Mammalia Species 0.000 claims abstract description 46
208000030507 AIDS Diseases 0.000 claims abstract description 26
230000003308 immunostimulating effect Effects 0.000 claims abstract description 23
230000002708 enhancing effect Effects 0.000 claims abstract description 16
101710091045 Envelope protein Proteins 0.000 claims abstract description 11
101710188315 Protein X Proteins 0.000 claims abstract description 11
230000002401 inhibitory effect Effects 0.000 claims abstract description 7
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 57
230000004044 response Effects 0.000 claims description 30
241000700605 Viruses Species 0.000 claims description 22
210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 20
241000288906 Primates Species 0.000 claims description 15
229940046166 oligodeoxynucleotide Drugs 0.000 claims description 15
125000003729 nucleotide group Chemical group 0.000 claims description 12
239000002773 nucleotide Substances 0.000 claims description 11
108010055166 Chemokine CCL5 Proteins 0.000 claims description 8
102000001327 Chemokine CCL5 Human genes 0.000 claims description 8
230000016784 immunoglobulin production Effects 0.000 claims description 8
241000283984 Rodentia Species 0.000 claims description 6
241000282412 Homo Species 0.000 claims description 4
229940037003 alum Drugs 0.000 claims description 4
241000186359 Mycobacterium Species 0.000 claims description 3
210000002421 cell wall Anatomy 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
229940035032 monophosphoryl lipid a Drugs 0.000 claims description 3
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 2
102100021696 Syncytin-1 Human genes 0.000 claims 3
108091007433 antigens Proteins 0.000 abstract description 118
102000036639 antigens Human genes 0.000 abstract description 118
239000000427 antigen Substances 0.000 abstract description 117
101710147327 Calcineurin B homologous protein 1 Proteins 0.000 abstract description 45
101710205625 Capsid protein p24 Proteins 0.000 abstract description 45
101710177166 Phosphoprotein Proteins 0.000 abstract description 45
101710149279 Small delta antigen Proteins 0.000 abstract description 45
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 abstract description 45
102000001902 CC Chemokines Human genes 0.000 abstract 2
108010040471 CC Chemokines Proteins 0.000 abstract 2
102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 abstract 1
230000028993 immune response Effects 0.000 description 38
210000004027 cell Anatomy 0.000 description 33
210000001744 T-lymphocyte Anatomy 0.000 description 27
241001465754 Metazoa Species 0.000 description 25
208000031886 HIV Infections Diseases 0.000 description 19
208000037357 HIV infectious disease Diseases 0.000 description 19
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 19
230000003053 immunization Effects 0.000 description 16
238000011282 treatment Methods 0.000 description 16
102000004127 Cytokines Human genes 0.000 description 15
108090000695 Cytokines Proteins 0.000 description 15
230000004048 modification Effects 0.000 description 13
238000012986 modification Methods 0.000 description 13
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 12
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 12
229960005486 vaccine Drugs 0.000 description 12
208000015181 infectious disease Diseases 0.000 description 10
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 9
230000000694 effects Effects 0.000 description 9
210000003754 fetus Anatomy 0.000 description 9
VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 description 9
230000003389 potentiating effect Effects 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
230000000638 stimulation Effects 0.000 description 9
208000010648 susceptibility to HIV infection Diseases 0.000 description 9
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 8
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 8
102100034349 Integrase Human genes 0.000 description 8
230000023385 chemokine (C-C motif) ligand 5 production Effects 0.000 description 8
229940104302 cytosine Drugs 0.000 description 8
238000002649 immunization Methods 0.000 description 8
210000001165 lymph node Anatomy 0.000 description 8
206010061818 Disease progression Diseases 0.000 description 7
230000005750 disease progression Effects 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
102000019034 Chemokines Human genes 0.000 description 6
108010012236 Chemokines Proteins 0.000 description 6
108020004414 DNA Proteins 0.000 description 6
230000005875 antibody response Effects 0.000 description 6
231100000673 dose–response relationship Toxicity 0.000 description 6
239000012634 fragment Substances 0.000 description 6
230000001900 immune effect Effects 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
210000004988 splenocyte Anatomy 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241000283707 Capra Species 0.000 description 5
229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 5
238000007792 addition Methods 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000002596 correlated effect Effects 0.000 description 5
238000011694 lewis rat Methods 0.000 description 5
239000002245 particle Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
230000000069 prophylactic effect Effects 0.000 description 5
238000012286 ELISA Assay Methods 0.000 description 4
108091034117 Oligonucleotide Proteins 0.000 description 4
241001504519 Papio ursinus Species 0.000 description 4
239000012980 RPMI-1640 medium Substances 0.000 description 4
241000700159 Rattus Species 0.000 description 4
230000000996 additive effect Effects 0.000 description 4
229960002685 biotin Drugs 0.000 description 4
235000020958 biotin Nutrition 0.000 description 4
239000011616 biotin Substances 0.000 description 4
239000006285 cell suspension Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
230000009696 proliferative response Effects 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
229940021747 therapeutic vaccine Drugs 0.000 description 4
108010027044 HIV Core Protein p24 Proteins 0.000 description 3
229940033330 HIV vaccine Drugs 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
229930182816 L-glutamine Natural products 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
230000024932 T cell mediated immunity Effects 0.000 description 3
230000001464 adherent effect Effects 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000001461 cytolytic effect Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000036541 health Effects 0.000 description 3
230000028996 humoral immune response Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
229940021993 prophylactic vaccine Drugs 0.000 description 3
229960000380 propiolactone Drugs 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
241000894007 species Species 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
101710132601 Capsid protein Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
238000011510 Elispot assay Methods 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
241000282520 Papio Species 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
230000006052 T cell proliferation Effects 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
-1 aluminum salts Chemical class 0.000 description 2
230000036436 anti-hiv Effects 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
239000012636 effector Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
229940044627 gamma-interferon Drugs 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
238000004969 ion scattering spectroscopy Methods 0.000 description 2
230000008774 maternal effect Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
KDWFDOFTPHDNJL-TUBOTVQJSA-N odn-2006 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 KDWFDOFTPHDNJL-TUBOTVQJSA-N 0.000 description 2
238000004091 panning Methods 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
238000000053 physical method Methods 0.000 description 2
229920002627 poly(phosphazenes) Polymers 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
238000009589 serological test Methods 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
206010001513 AIDS related complex Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
102000004274 CCR5 Receptors Human genes 0.000 description 1
108010017088 CCR5 Receptors Proteins 0.000 description 1
241001428800 Cell fusing agent virus Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
206010071602 Genetic polymorphism Diseases 0.000 description 1
229940033332 HIV-1 vaccine Drugs 0.000 description 1
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
241000282553 Macaca Species 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
108010047620 Phytohemagglutinins Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
101001043830 Rattus norvegicus Interleukin-2 Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
238000010171 animal model Methods 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
230000007416 antiviral immune response Effects 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001889 chemoattractive effect Effects 0.000 description 1
230000014564 chemokine production Effects 0.000 description 1
210000000991 chicken egg Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
101150008740 cpg-1 gene Proteins 0.000 description 1
101150071119 cpg-2 gene Proteins 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000011266 cytolytic assay Methods 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
108700004026 gag Genes Proteins 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
229940059904 light mineral oil Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000003921 oil Substances 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
239000008188 pellet Substances 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
230000001885 phytohemagglutinin Effects 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
150000003071 polychlorinated biphenyls Chemical group 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000009877 rendering Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
238000000527 sonication Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000002522 swelling effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000010257 thawing Methods 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
108091007466 transmembrane glycoproteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002372960A 1999-05-06 2000-05-05 Hiv immunogenic compositions and methods Expired - Fee Related CA2372960C (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US13276299P	1999-05-06	1999-05-06
US60/132,762		1999-05-06
US15066799P	1999-08-25	1999-08-25
US60/150,667		1999-08-25
PCT/US2000/012495 WO2000067787A2 (en)	1999-05-06	2000-05-05	Hiv immunogenic compositions and methods

Publications (2)

Publication Number	Publication Date
CA2372960A1 CA2372960A1 (en)	2000-11-16
CA2372960C true CA2372960C (en)	2006-03-28

Family

ID=26830710

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002372960A Expired - Fee Related CA2372960C (en)	1999-05-06	2000-05-05	Hiv immunogenic compositions and methods

Country Status (8)

Country	Link
EP (1)	EP1176978A2 (es)
AP (1)	AP1891A (es)
AU (1)	AU4992900A (es)
BR (1)	BR0010323A (es)
CA (1)	CA2372960C (es)
CR (1)	CR6491A (es)
OA (1)	OA11937A (es)
WO (1)	WO2000067787A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
DK1733735T3 (en)	1998-05-22	2017-06-19	Ottawa Hospital Res Inst	Methods and products for the induction of mucosal immunity
WO2000039304A2 (en)	1998-12-31	2000-07-06	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1980617A1 (en)	1998-12-31	2008-10-15	Novartis Vaccines and Diagnostics, Inc.	Improved expression of HIV polypeptides and production of virus-like particles
ES2572834T3 (es)	1999-02-17	2016-06-02	Csl Limited	Complejos inmunogénicos y métodos relacionados con los mismos
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
WO2001000232A2 (en) *	1999-06-29	2001-01-04	Smithkline Beecham Biologicals S.A.	Use of cpg as an adjuvant for hiv vaccine
EP1322655B1 (en)	2000-01-14	2007-11-14	The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services	Oligodeoxynucleotide and its use to induce an immune response
NZ526322A (en)	2000-12-27	2005-06-24	Dynavax Tech Corp	Immunomodulatory polynucleotides and methods of using the same
SG152045A1 (en) *	2001-01-26	2009-05-29	Immune Response Corp Inc	Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment
EP1404873B1 (en)	2001-06-21	2013-05-22	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same
CA2452015C (en)	2001-07-05	2012-07-03	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2003020884A2 (en)	2001-08-14	2003-03-13	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Method for rapid generation of mature dendritic cells
ES2314099T3 (es)	2001-08-17	2009-03-16	Coley Pharmaceutical Gmbh	Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
US20030170614A1 (en)	2001-08-31	2003-09-11	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
AR045702A1 (es)	2001-10-03	2005-11-09	Chiron Corp	Composiciones de adyuvantes.
AU2002366710A1 (en)	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
CA2388049A1 (en)	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
JP2005532067A (ja) *	2002-07-03	2005-10-27	コーリーファーマシューティカルグループ，インコーポレイテッド	刺激性免疫応答用の核酸組成物
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en)	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en)	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
CA2503693A1 (en)	2002-10-29	2004-05-13	Coley Pharmaceutical Group, Ltd.	Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
JP2006512927A (ja)	2002-12-11	2006-04-20	コーリーファーマシューティカルグループ，インコーポレイテッド	５’ｃｐｇ核酸およびその使用方法
ATE544772T1 (de)	2002-12-23	2012-02-15	Dynavax Tech Corp	Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür
US8158768B2 (en)	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
WO2005021726A2 (en) *	2003-08-28	2005-03-10	The Immune Response Corporation	Immunogenic hiv compositions and related methods
MY159370A (en)	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
CN101517082B (zh)	2006-09-27	2014-01-22	科勒制药有限责任公司	具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
WO2010051820A1 (en) *	2008-11-10	2010-05-14	Aarhus Universitet	Multiplexed cytokine vaccination
AU2012280901B2 (en)	2011-07-06	2016-11-10	Glaxosmithkline Biologicals S.A.	Oil-in-water emulsions that contain nucleic acids
RU2649133C2 (ru)	2011-07-06	2018-03-29	Новартис Аг	Катионные эмульсии масло-в-воде

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU753688B2 (en) *	1997-03-10	2002-10-24	Ottawa Civic Loeb Research Institute	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998055495A2 (en) *	1997-06-06	1998-12-10	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof

2000
- 2000-05-05 AU AU49929/00A patent/AU4992900A/en not_active Abandoned
- 2000-05-05 AP APAP/P/2001/002300A patent/AP1891A/en active
- 2000-05-05 BR BR0010323-3A patent/BR0010323A/pt not_active IP Right Cessation
- 2000-05-05 WO PCT/US2000/012495 patent/WO2000067787A2/en not_active Ceased
- 2000-05-05 OA OA1200100291A patent/OA11937A/en unknown
- 2000-05-05 EP EP00932163A patent/EP1176978A2/en not_active Withdrawn
- 2000-05-05 CA CA002372960A patent/CA2372960C/en not_active Expired - Fee Related
2001
- 2001-10-25 CR CR6491A patent/CR6491A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2372960A1 (en)	2000-11-16
WO2000067787A3 (en)	2001-04-26
OA11937A (en)	2006-04-12
AP2001002300A0 (en)	2001-12-31
AP1891A (en)	2008-09-23
AU4992900A (en)	2000-11-21
EP1176978A2 (en)	2002-02-06
BR0010323A (pt)	2002-01-08
WO2000067787A2 (en)	2000-11-16
CR6491A (es)	2005-05-31

Legal Events

Date	Code	Title	Description
2002-05-02	EEER	Examination request
2009-05-05	MKLA	Lapsed

Publication	Publication Date	Title
US6737066B1 (en)	2004-05-18	HIV immunogenic compositions and methods
AU4992900A (en)	2000-11-21	Hiv immunogenic compositions and methods
Boyer et al.	1999	Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial
EP1578766B1 (en)	2013-02-13	Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
US20140227307A1 (en)	2014-08-14	Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
NO314588B1 (no)	2003-04-14	HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
Borsutzky et al.	2006	Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant
Fast et al.	1993	Human trials of experimental AIDS vaccines
Zolla-Pazner et al.	1997	Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines
US20050196411A1 (en)	2005-09-08	Immunogenic HIV compositions and related methods
Valentine et al.	1996	A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with⩾ 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)
US20030044428A1 (en)	2003-03-06	Method for treating an HIV-infected individual by combining immunization with structured interruption of anti-retroviral treatment
AU2005222909B2 (en)	2010-03-11	Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide
US20080026448A1 (en)	2008-01-31	Production of HIV
Robinson et al.	2003	Parasitic infection and the polarized Th2 immune response can alter a vaccine-induced immune response
ZA200108559B (en)	2002-06-06	HIV immunogenic compositions and methods.
MXPA01010784A (es)	2002-06-05	Composiciones inmunogenicas contra vih y metodos
Trabattoni et al.	2006	Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice
KR20070019635A (ko)	2007-02-15	면역원성 ｈｉｖ 조성물 및 이와 관련된 방법
HK1114789A (en)	2008-11-14	Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
WO1994002171A1 (en)	1994-02-03	Prophylactic and therapeutic control of retroviral infections